{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:44:06Z","timestamp":1740149046449,"version":"3.37.3"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T00:00:00Z","timestamp":1435276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Med Imag Rad Onc"],"published-print":{"date-parts":[[2015,10]]},"abstract":"Abstract<\/jats:title>Introduction<\/jats:title>Retrospective analysis was performed at a single institution to assess the responsiveness of mantle cell lymphoma (MCL<\/jats:styled-content>) to involved\u2010field radiotherapy (IFRT<\/jats:styled-content>).<\/jats:p><\/jats:sec>Methods<\/jats:title>All patients treated with IFRT<\/jats:styled-content> to at least one site of MCL<\/jats:styled-content> between 1998 and 2012 were included. There were 25 patients who received radiotherapy to 60 disease sites. Primary endpoint was overall response rate (ORR<\/jats:styled-content>) infield for the first site of MCL<\/jats:styled-content> treated per patient. Predictors of ORR<\/jats:styled-content> were analysed for the primary endpoint. Time to local progression (TLP<\/jats:styled-content>) infield and progression\u2010free survival were calculated from the start of the first treatment course. Analysis of all sites collectively was also undertaken. Survival analysis was conducted by the K<\/jats:styled-content>aplan\u2013M<\/jats:styled-content>eier method.<\/jats:p><\/jats:sec>Results<\/jats:title>ORR<\/jats:styled-content> rate was 84% for the first site treated per patient. Complete response and partial response rates were 68% and 16% respectively. Median TLP<\/jats:styled-content> following radiotherapy to the first site was not reached. Infield control rate was 91% at 12 months (95% confidence interval 69\u201397%). When analysis was performed on all 60 sites, ORR<\/jats:styled-content> was 85%. Symptomatic improvement occurred after IFRT<\/jats:styled-content> to 93% of all sites. Systemic progression outside the radiotherapy field was the predominant form of failure following IFRT<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Radiotherapy generally induced a clinical response at all levels of dose administered, ranging from 3 to 36\u2009G<\/jats:styled-content>y. However, increased durability of local control was suggested with higher doses. Radiotherapy is an effective treatment for palliation of MCL<\/jats:styled-content> with objective and symptomatic responses seen over a range of radiotherapy doses.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1754-9485.12335","type":"journal-article","created":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T10:01:06Z","timestamp":1435312866000},"page":"631-639","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Involved\u2010field radiotherapy for patients with mantle cell lymphoma"],"prefix":"10.1111","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-8989","authenticated-orcid":false,"given":"Katherine E","family":"Neville","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology Royal North Shore Hospital St Leonards New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Bisquera","sequence":"additional","affiliation":[{"name":"The Hunter Medical Research Institute New Lambton Heights New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne L","family":"Capp","sequence":"additional","affiliation":[{"name":"The University of Newcastle Callaghan New South Wales Australia"},{"name":"Department of Radiation Oncology Calvary Mater Newcastle Waratah New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,26]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"AIHW(ed).Australian Cancer Database.2010."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.12.013"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg414"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.711828"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.02.011"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.013"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.04.033"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.12.024"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206826"},{"key":"e_1_2_6_11_1","unstructured":"NHMRC.National Statement on Ethical Conduct in Human Research.2007."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.542"},{"key":"e_1_2_6_14_1","unstructured":"(AIHW) AIoHaW.Cancer survival and prevalence in Australia: period estimates from 1982 to 2010: supplementary data tables: non\u2010Hodgkin lymphoma. Canberra: AIHW;2012. [Cited 3 Jan 2014.] Available from URL:http:\/\/www.aihw.gov.au\/WorkArea\/DownloadAsset.aspx?id=10737422741"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70036-1"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23615"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314608110"}],"container-title":["Journal of Medical Imaging and Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1754-9485.12335","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.12335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T20:35:19Z","timestamp":1696278919000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1754-9485.12335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,26]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/1754-9485.12335"],"URL":"https:\/\/doi.org\/10.1111\/1754-9485.12335","archive":["Portico"],"relation":{},"ISSN":["1754-9477","1754-9485"],"issn-type":[{"type":"print","value":"1754-9477"},{"type":"electronic","value":"1754-9485"}],"subject":[],"published":{"date-parts":[[2015,6,26]]},"assertion":[{"value":"2014-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}